2
Clinical Trials associated with CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)Safety and Efficacy of CAR2219 CAR-T Cells in Treatment of Relapsed/refractory CD19/CD22 Positive B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
/ Not yet recruitingPhase 1IIT A Study of CAR2219 CAR-T cell in subjects with relapsed/refractory CD19/CD22 positive B cell Lymphoma
Start Date31 Oct 2024 |
Sponsor / Collaborator- |
100 Clinical Results associated with CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)
100 Translational Medicine associated with CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)
100 Patents (Medical) associated with CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)
100 Deals associated with CAR2219 CAR-T Cells(Affiliated Hospital to Academy of Military Medical Sciences)